Analysts Issue Forecasts for Adagene FY2025 Earnings

Adagene Inc. Sponsored ADR (NASDAQ:ADAG) – Equities research analysts at Lifesci Capital issued their FY2025 EPS estimates for Adagene in a research note issued on Tuesday, December 16th. Lifesci Capital analyst C. Zhu anticipates that the company will post earnings of ($0.45) per share for the year. Lifesci Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Adagene’s current full-year earnings is ($0.60) per share. Lifesci Capital also issued estimates for Adagene’s FY2026 earnings at ($0.71) EPS.

Several other analysts have also recently issued reports on the company. Guggenheim started coverage on Adagene in a report on Monday, November 24th. They set a “buy” rating and a $9.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Adagene in a research report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $7.67.

Adagene Price Performance

Shares of NASDAQ ADAG opened at $1.82 on Thursday. The firm has a fifty day moving average price of $1.83 and a 200-day moving average price of $1.95. Adagene has a 1 year low of $1.30 and a 1 year high of $3.16.

Institutional Investors Weigh In On Adagene

Several hedge funds have recently modified their holdings of ADAG. Gordian Capital Singapore Pte Ltd purchased a new stake in shares of Adagene in the first quarter valued at approximately $29,000. Marex Group plc purchased a new position in Adagene in the 2nd quarter worth approximately $47,000. Finally, Citadel Advisors LLC acquired a new position in Adagene during the third quarter worth $80,000. 9.51% of the stock is owned by hedge funds and other institutional investors.

Adagene Company Profile

Adagene Inc, headquartered in Suzhou, China, is a clinical-stage biopharmaceutical company specializing in the discovery and development of antibody-based therapeutics for cancer and immune-related diseases. Founded in 2017, the company leverages its proprietary immunome technology platform to mine human antibody repertoires and engineer novel monospecific and bispecific antibodies. Adagene’s pipeline includes multiple candidates in preclinical and early clinical development, with a focus on targeting tumor microenvironments and modulating immune checkpoints to enhance anti-tumor efficacy.

At the core of Adagene’s research and development efforts is its Bihanc™ antibody platform, which combines combinatorial phage display, structure-based design and artificial intelligence to optimize binding affinity, specificity and developability.